(Q34712834)

4 August 2017

title

Tumor hypoxia in cancer therapy (English)

1 reference

4 August 2017

0 references

J Martin Brown

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

4 August 2017

1 reference

inferred from page(s)

published in

Methods in Enzymology

1 reference

4 August 2017

volume

435

1 reference

4 August 2017

page(s)

297-321

1 reference

The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Hypoxia-mediated tumour targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Selective Radiosensitization of the Hypoxic Cells of Mouse Tumors with the Nitroimidazoles Metronidazole and Ro 7-0582

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Tumor microenvironment and the response to anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Exploiting tumour hypoxia in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Acute hypoxia in tumors: implications for modifiers of radiation effects

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The potential benefit from a perfect radiosensitizer and its dependence on reoxygenation

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

HIF-1 as a target for drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The macrophage - a novel system to deliver gene therapy to pathological hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Hypoxia--a key regulatory factor in tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Does hyperbaric oxygen have a future in radiation therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Tumour radiosensitization by high-oxygen-content gases: influence of the carbon dioxide content of the inspired gas on PO2, microcirculatory function and radiosensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Rapid-mixing studies of radiosensitivity with thiol-depleted mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The Phenomenon of Reoxygenation and Its Implications for Fractionated Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The effect on the Km for radiosensitization at 0 degree C of thiol depletion by diethylmaleate pretreatment: quantitative differences found using the radiation sensitizing agent misonidazole or oxygen

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Suppression of tumor growth through disruption of hypoxia-inducible transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Hypoxic gene expression and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Inhibiting hypoxia-inducible factor 1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Clostridia in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Tumor hypoxia: its impact on cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Tumour cytochrome P450 and drug activation

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

XBP1 is essential for survival under hypoxic conditions and is required for tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Therapeutic gain factors for fractionated radiation treatment of spontaneous murine tumors using fast neutrons, photons plus O2(1) or 3 ATA, or photons plus misonidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Conventional cancer therapy: promise broken or promise delayed?

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

The histological structure of some human lung cancers and the possible implications for radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Use of a carbocyanine dye as a marker of functional vasculature in murine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

A rapid-mixing comparison of the mechanisms of radiosensitization by oxygen and misonidazole in CHO cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2807%2935015-5

7 January 2021

10.1016/S0076-6879(07)35015-5

Identifiers

DOI

1 reference

4 August 2017

1 reference